Notícias e eventos

Página Inicial / Notícias e eventos

BVI Announces Investment & Collaboration with Beyeonics Vision

Supports surgeon-centered digital visualization, improved ergonomics and real-timeguidance to surgical decision-making process

WALTHAM, Mass.–(BUSINESS WIRE)–BVI, a purpose-built diversified global ophthalmic device company, todayannounced an investment in Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd. (NASDAQ: ESLT andTASE: ESLT) (“Elbit Systems”). Beyeonics Vision uses integrated augmented reality, tracking, and image processing/AIplatforms to deliver improved visualization, optimized workflow, and real-time support to surgeon decision-making processin the operating room. The collaboration also promotes a streamlined process to commercialize Beyeonics One in theUnited States, with potential for rapid expansion in territories outside of the United States.

“BVI routinely assesses opportunities to partner with companies that have a commitment to innovation and share ourentrepreneurial mindset. With Beyeonics One, BVI can expand our offering of unparalleled surgical experience duringanterior and posterior segment procedures,” said Shervin Korangy, BVI’s President and Chief Executive Officer. “We knowfrom experience that it takes shared priorities to deliver on our mission and are excited that Beyeonics Vision shares ourpassion for and commitment to refocusing the future of vision.”

Beyeonics Vision has been developing Beyeonics One, the first and only commercial ophthalmic digital imaging system toreplace optical analog microscopes. Beyeonics One is an open and upgradable digital visualization platform, equipped withan ultra-high-resolution camera that processes and transfers digitally enhanced images to a high-resolution head-wearabledisplay for a truly immersive and natural stereoscopic 3-D viewing experience. Beyeonics One provides surgeons withenhanced automation, programming autonomy and more freedom to set-up the operating room and adopt a moreergonomically efficient posture. Additionally, the system enables real-time decision-making process with customizableintegration of accessible pre-/intra-operative data and seamless integration with other devices.

“We are excited to partner with BVI on the U.S. commercialization of Beyeonics One and the potential to collaborate onfuture innovations as well. Through this collaboration we aim to expand our collective capabilities to optimize all aspects ofvisualization for eye surgeons and offer a transformative experience to providers and patients,” shared Ron Schneider,CEO of Beyeonics Vision.
BVI first previewed their partnership with Beyeonics Vision at the American Society of Cataract and Refractive Surgeryannual meeting in July 2021 and will continue this at ESCRS in Amsterdam in October, & AAO in New Orleans in November.

About BVI
BVI® is a global ophthalmic medical device manufacturer with a mission to deliver high quality solutions and innovation foradvancing eye surgery and improving the vision of patients. With nine decades of developing leading products andsolutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Ourorganization supports surgical teams, in more than 115 countries worldwide, either directly or through our network oftrusted distributors. Our trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-UseInstruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).

About Beyeonics Vision

Beyeonics Vision, a subsidiary from Elbit Systems (NASDAQ:ESLT), is a medical technology company developingsurgeon-centered visualization solutions. Beyeonics is aiming to consolidate & democratize surgery, deliver atransformative technology by using integrated augmented reality, tracking and image processing visualization platform totell surgeons valuable information, to guide decisions and to perform automatic tasks.

Contacts
BVI
Andrew Dawson
Corporate Communications
[email protected]

Investors
Gilmartin Group
Vivian Cervantes
[email protected]

← Voltar para as notícias